Thus, HER2-targeted therapy in HER2-positive patients is not always effective in MBC therapy, mostly due to cancer heterogeneity, its constantly evolving nature, and subjectivity in evaluating the results of immunohistochemistry (IHC) and/or fluorescent in situ hybridization (FISH). The gene discussed is ERBB2; the disease is cancer.